Limited effectiveness with a 10 ‐day bismuth‐containing quadruple therapy (Pylera®) in third‐line recue treatment for Helicobacter pylori infection. A real‐life multicenter study

ConclusionIn an area of high antibiotic resistance to H. pylori, 10‐day Pylera® plus double‐dose PPI emerged as an alternative as third‐line therapy, although not achieving optimal eradication rates. TRAEs were common but were neither severe nor did they condition compliance.

Source: Helicobacter - August 1, 2017 Category: Gastroenterology Authors: Enrique Rodr íguez de Santiago, Carlos Martín de Argila de Prados, Hector Miguel Marcos Prieto, Miguel Ãngel Jorge Turrión, Eva Barreiro Alonso, Alvaro Flores de Miguel, Cristobal Coba Ortiz, Carlos Rodríguez Escaja, Gustavo Pérez Álvarez, Carlos F Tags: ORIGINAL ARTICLE Source Type: research